Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux

This publication has 10 references indexed in Scilit:

• Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
  Blood, 2005
• Use of fondaparinux (ARIXTRA(R)) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II
  Nephrology Dialysis Transplantation, 2005
• Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin
  Blood, 2005
• Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia
  Blood, 2005
• Fondaparinux Sodium
  Drugs, 2004
• Biological and clinical features of low‐molecular‐weight heparin‐induced thrombocytopenia
  British Journal of Haematology, 2003
• Heparin‐induced thrombocytopenia: pathogenesis and management
  British Journal of Haematology, 2003
• Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia
  Thrombosis Research, 1996
• Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia
  Thrombosis and Haemostasis, 1995
• Mode of interaction between platelet factor 4 and heparin
  Glycobiology, 1993